A Phase 1b, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis
Clinical Trial Grant
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 10, 2020
End Date
March 30, 2021
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 10, 2020
End Date
March 30, 2021